RPRXN Stock Chart & Stats
$1025.44
$0.00(0.00%)
At close: 4:00 PM EDT
$1025.44
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$624.01 - $1,025.44
Previous CloseN/A
Volume0.00
Average Volume (3M)161.00
Market Cap
$583.72B
Enterprise Value$38.11K
Total Cash (Recent Filing)$608.29M
Total Debt (Recent Filing)$8.96B
Price to Earnings (P/E)23.7
Beta0.19
Next Earnings
Aug 05, 2026EPS Estimate
22.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.46
Shares Outstanding443,274,100
10 Day Avg. Volume483
30 Day Avg. Volume161
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.58
Price to Sales (P/S)7.02
P/FCF Ratio6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,082.71Price Target Upside5.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)90.86
Revenue Forecast (FY)$60.31B
Royalty Pharma News
RPRXN FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $624.01 and its highest was $1025.44 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $583.72B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on May 06, 2026. The company reported $22.482 earnings per share for the quarter, beating the consensus estimate of $21.06 by $1.422.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC does not currently pay dividends.
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 22.08.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 443,274,100 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $22.482 in its last earnings report, beating expectations of $21.06. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in MX:RPRXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,082.71 (5.59% Upside)
$1,082.71 (5.59% Upside)
Blogger Sentiment
Bullish
MX:RPRXN Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.59%
12-Months-Change
Fundamentals
Return on Equity
1.42%
Trailing 12-Months
Asset Growth
12.53%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRXN Company Deck
RPRXN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive: Royalty Pharma reported double-digit recurring revenue growth, attractive returns (ROIC ~14.1%, ROIE ~19.7%), robust cash generation ($722M portfolio cash flow), active capital deployment (>$0.5B) and strategic deal flow including R&D co-funding momentum (J&J and Teva deals) and high-impact clinical/regulatory wins (daraxonrasib, Avlayah, Myqorzo). Key risks highlighted were a material decline in milestone receipts (~53% drop), elevated interest expense timing, some market/policy headwinds (Promacta LOE, biosimilar Tysabri, MFN uncertainty) and optionality/execution risk in future co-funding tranches. Overall, the positive operating and balance-sheet trends and raised guidance outweigh the limited but meaningful risks discussed.View all MX:RPRXN earnings summariesRPRXN Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets

RPRXN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$1,082.71
▲(5.59% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month









